| pubmed-article:12877582 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12877582 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:12877582 | lifeskim:mentions | umls-concept:C0302600 | lld:lifeskim |
| pubmed-article:12877582 | lifeskim:mentions | umls-concept:C0127863 | lld:lifeskim |
| pubmed-article:12877582 | lifeskim:mentions | umls-concept:C1999216 | lld:lifeskim |
| pubmed-article:12877582 | lifeskim:mentions | umls-concept:C1311028 | lld:lifeskim |
| pubmed-article:12877582 | pubmed:issue | 16 | lld:pubmed |
| pubmed-article:12877582 | pubmed:dateCreated | 2003-7-24 | lld:pubmed |
| pubmed-article:12877582 | pubmed:abstractText | Fumagillin and ovalicin constitute a family of structurally related natural products that possess antiangiogenic activity. We report the synthesis of a new fumagillin analogue, fumagalone, in which the spiroepoxide group is replaced with an aldehyde. Fumagalone inhibits type 2 methionine aminopeptidase (MetAP2) with IC(50) = 8 microM and endothelial cell proliferation with IC(50) = 52 nM. With dialysis and competition assays, it was unambiguously demonstrated that binding of fumagalone to MetAP2 is reversible. | lld:pubmed |
| pubmed-article:12877582 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12877582 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12877582 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12877582 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12877582 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12877582 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12877582 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12877582 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12877582 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12877582 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12877582 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12877582 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12877582 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12877582 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12877582 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:12877582 | pubmed:issn | 0022-2623 | lld:pubmed |
| pubmed-article:12877582 | pubmed:author | pubmed-author:ZhouGuochunG | lld:pubmed |
| pubmed-article:12877582 | pubmed:author | pubmed-author:LiuJun OJO | lld:pubmed |
| pubmed-article:12877582 | pubmed:author | pubmed-author:TsaiChiawei... | lld:pubmed |
| pubmed-article:12877582 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12877582 | pubmed:day | 31 | lld:pubmed |
| pubmed-article:12877582 | pubmed:volume | 46 | lld:pubmed |
| pubmed-article:12877582 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12877582 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12877582 | pubmed:pagination | 3452-4 | lld:pubmed |
| pubmed-article:12877582 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:12877582 | pubmed:meshHeading | pubmed-meshheading:12877582... | lld:pubmed |
| pubmed-article:12877582 | pubmed:meshHeading | pubmed-meshheading:12877582... | lld:pubmed |
| pubmed-article:12877582 | pubmed:meshHeading | pubmed-meshheading:12877582... | lld:pubmed |
| pubmed-article:12877582 | pubmed:meshHeading | pubmed-meshheading:12877582... | lld:pubmed |
| pubmed-article:12877582 | pubmed:meshHeading | pubmed-meshheading:12877582... | lld:pubmed |
| pubmed-article:12877582 | pubmed:meshHeading | pubmed-meshheading:12877582... | lld:pubmed |
| pubmed-article:12877582 | pubmed:meshHeading | pubmed-meshheading:12877582... | lld:pubmed |
| pubmed-article:12877582 | pubmed:meshHeading | pubmed-meshheading:12877582... | lld:pubmed |
| pubmed-article:12877582 | pubmed:meshHeading | pubmed-meshheading:12877582... | lld:pubmed |
| pubmed-article:12877582 | pubmed:meshHeading | pubmed-meshheading:12877582... | lld:pubmed |
| pubmed-article:12877582 | pubmed:meshHeading | pubmed-meshheading:12877582... | lld:pubmed |
| pubmed-article:12877582 | pubmed:meshHeading | pubmed-meshheading:12877582... | lld:pubmed |
| pubmed-article:12877582 | pubmed:meshHeading | pubmed-meshheading:12877582... | lld:pubmed |
| pubmed-article:12877582 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12877582 | pubmed:articleTitle | Fumagalone, a reversible inhibitor of type 2 methionine aminopeptidase and angiogenesis. | lld:pubmed |
| pubmed-article:12877582 | pubmed:affiliation | Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. | lld:pubmed |
| pubmed-article:12877582 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12877582 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:12877582 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:12877582 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:12877582 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12877582 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12877582 | lld:pubmed |
